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and Brezenoff (1980) demonstrated that central intracerebroventricular (icv) injection of choline induced a short lasting, but significant increase in arterial pressure and a much longer lasting bradycardic response in unanesthetized rats. They failed to inhibit the pressor response through pretreatment of the animals by icv injection with either the muscarinic antagonist atropine or the nicotinic antagonist mecamylamine. Neither drug alone nor their combination modified the pressor response. However, neither of these compounds is subtype selective within their respective class, and atropine induces acetylcholine release. In light of the recently discovered ability of choline to serve as a selective agonist at α7nAChRs (Papke et al., 1996; Alkondon et al., 1999; Pereira et al., 2002) , it is reasonable to consider that this receptor subtype mediates the choline-induced pressor response. With reasonably subtype selective nAChR antagonists now available this possibility can readily be examined. Thus, the first portion of this study was directed at determining whether the cardiovascular response to icv administration of choline was mediated predominantly through activation of α7nAChRs.
In the Alzheimer's disesase (AD) brain large deposits of amyloid plaques are present that consist chiefly of amyloid β peptides. In fact, recently, amyloid β peptides containing a crucial binding sequence, including the neurotoxic Aβ1-42, have been shown to bind with high affinity to α7 nAChRs (Wang et al., 1999; Wang et al., 2000) . Moreover, Aβ and α7nAChRs appear to colocalize within the AD brain. Aβ peptides have been shown to inhibit the cellular responses to nAChR agonists (Pettit, et al., 2000; Liu, et al., 2001) and to prevent the cytoprotective action of nicotine in vitro (Li and Buccafusco, 2003) . There also exists evidence to suggest that amyloid deposition in AD-related transgenic mouse strains alters the expression of nicotinic receptors in JPET #63321 8 right of the first hole and a stainless steel anchoring screw was inserted. A sterile stainless steel or cannula guide was attached to a micromanipulator on the stereotaxic frame. Each guide (Plastics One, Roanoke, VA) had a stainless steel shaft equivalent to 22 gauge tubing which was inserted into a wider threaded region made of Teflon at the top of the guide. The threaded region permits the introduction of a screw cap and dummy cannula to plug the guide when not in use.
The cannula guide (11 mm long) was lowered to a depth of 4.0 mm below the skull through the burr hole over the ventricle. The tip of the guide was placed over, but without penetrating, the ventricular space. While in position, the guide and screw were covered with acrylic cement.
After complete hardening of the cement, the manipulator was retracted and the guide plugged and capped. The skin was pulled around (but not over) the guide and sutured closed.
One week later rats again were anesthetized and a surgical incision was made in the midline of the abdomen to expose the lower portion of the abdominal aorta. A small nick was made in the lower portion of the aorta and a telemetry catheter (implant model TA11PA-C40, Data Sciences International, St. Paul, MN) was introduced and advanced until the tip rested below the origin of the renal arteries. The tip of the catheter contains a non-thrombogenic gel to prevent clot formation. The catheter end was fixed in place in the aorta by using Vetbond tissue adhesive (3M Animal Care Products, St. Paul, MN). The transmitter end of the catheter was placed subcutaneously over the abdomen and the wound was sutured closed.
Measurement of mean arterial pressure and heart rate:
Blood pressure and heart rate were measured using the DSI PhysioTel ® telemetry system (Data JPET #63321
within their cages. Each implanted transducer/transceiver transmitted pre-calibrated digitized blood pressure data via radio frequency signals to a nearby receiver. The data was sampled continuously, and by using the Dataquest ® data acquisition system (Data Sciences International, St. Paul, MN) which also calculated heart rate continuously from the pressure waveforms. Mean arterial pressure (MAP) and heart rate values were averaged and presented graphically in 30 sec bins.
Microinjections:
For icv injections, a 50 µl Hamilton micro-syringe (Reno, NV) was connected to a 28 gauge internal cannula (Plastics One, Inc., Roanoke, VA), which was inserted into the cranial 22 gauge cannula guide so that the tip rested within the lateral ventricle. All test compounds were dissolved in 10 µl sterile normal saline (vehicle), and they were delivered by hand over a period of 15-20 sec. At the completion of experiments each injection site was verified by injecting 10 µl India ink. The pretreatment drugs (or vehicle) were administrated 10 or 30 min (as indicated)
prior to the choline (or vehicle) injection. Rats were allowed to recover for at least one day after each experiment (i.e., one choline microinjection). Each rat was used in no more than 5 experiments.
Statistical analysis:
The data depicted in the text and figures is presented as mean ± S.E.M. The existence of a significant difference between or among experimental groups was determined by analysis of variance with repeated measures. A modified t test with Bonferroni's correction for multiple comparisons using the error mean-square term from the analysis of variance was used for This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Because all of the data derived from this study are presented as the absolute change from resting (baseline) MAP and heart rate, Table 1 provides the baseline means for each of the experimental paradigms. There were no significant differences among the means for MAP [(F(10,65) =1.25, P=0
.28]. There also were no significant differences among means for resting heart rate [(F(10,65) heart rate initially increased (to about 40 beats/min) and it peaked about the same time as the increase in MAP (Fig. 2) . Thereafter, heart rate declined to below pre-injection values. The late decrease in heart rate may reflect a decrease in cardiac output driving the late fall in MAP observed in some animals. Although the heart rate changes were not statistically dose-dependent [F(2,10)=1.67, P=0.24], the profile of response to choline was quite similar to that reported 13 years ago by Caputi and Brezenoff (1980) except for the brief initial increase in heart rate which they did not report observing. It is possible that the increase in heart rate may have reflected animal activity just after the injection as it was not present in all animals. As observed by Caputi and Brezenoff (1980) , and in this study, the duration of the decrease in heart rate usually far exceeded (at least up to 30 min) the duration of the increase in MAP. Also, soon after choline administration, an increase in locomotor activity was often observed, with the effect quickly diminishing; and the rats actually remained quiet, possibly sedate for the remainder of the observation period. Although the behavioral effects were not quantified, they were not apparent after icv injection of vehicle.
To determine whether α7nAChRs contribute to the cardiovascular response produced by choline, rats were pretreated by icv injection either with methyllycaconitine (MLA) or α-bungarotoxin, both α7nAChR-specific antagonists. In the first series, administration of 10 µ g MLA (10 min prior to 150 µg of choline) resulted in a complete abolition of the pressor response to choline.
Likewise, the biphasic heart rate change after choline was essentially normalized by MLA pretreatment (Fig. 3) . In contrast, pretreatment with 0.3 µ g atropine failed to significantly modify the pressor response to choline. This icv dose of atropine was shown previously to completely block the pressor response to central microinjection of muscarinic agonists (Caputi and Brezenoff, 1980) . Atropine pretreatment partly, but significantly, reversed the changes in heart rate produced by choline. The administration of 10 µ g α-bungarotoxin (30 min prior to 150 µg of choline), like MLA, significantly inhibited the magnitude of the choline-induced pressor response. These data are presented in Figure 4 . The longer pretreatment time for α-bungarotoxin in this series was in consideration of the drug's slow binding kinetics. Toxin pretreatment significantly inhibited the choline-induced initial increase in heart rate, but it had no effect on the subsequent bradycardic response (Fig 4, inset) . To further examine the specificity This article has not been copyedited and formatted. The final version may differ from this version. of the choline response, the β2-subtype preferring antagonist DHβE was used as the pretreatment agent. Unlike MLA and α-bungarotoxin, pretreatment with 6 µ g of DHβE failed to significantly inhibit the pressor response to subsequent injection of 150 µg of choline (Fig. 4) . The heart rate changes induced by choline also were not affected by DHβE (Fig. 4, inset) .
With the data suggesting that the initial pressor response to icv microinjection of choline was mediated predominantly by α7nAChRs, we next sought to determine whether pretreatment with the amyloid peptide (also known to block α7nAChRs) would effectively inhibit the choline response. Aβ1-42 (1, 10, or 100 pmol) was administrated 30 min prior to choline. The peptide itself elicited no change in resting MAP or heart rate ( Table 1) (Gil et al., 2002 ), Alzheimer's disease (Meyer et al., 1997; Briggs et al., 1997; Kem, 2000) , and
Parkinsons's disease (Burghaus et al., 2003) . As new α7nAChR compounds become available it would be advantageous to have an efficient, objective, and experimentally simple model for drug efficacy. In this study, the most technically challenging procedure was the installation of the aortic blood pressure telemetry catheter. However, similar results may be obtained by using a standard catheter inserted into any major artery. In fact, for our very first dose finding experiments we directly catheterized the iliac artery and exteriorized the catheter to a water-tight swivel for the measurement of MAP in unanesthetized animals as we have described previously (Buccafusco and Yang, 1993) . The use of the telemetry catheter was somewhat more advantageous as there are no exterior catheters to maintain, and the preparation has a longer useful lifetime.
The most reproducible response produced by icv microinjection of choline was the pressor response that occurred during the first 10-15 min after injection. Except for the magnitude of the pressor response (which was greater than that to choline), the cardiovascular changes to icv administered nicotine as we described them several years ago (Buccafusco and Yang, 1993) were quite similar to those produced by icv administration of choline. The maximal pressor response to nicotine (averaging about 30 mmHg) was achieved with 50 µg (0.11 µmoles) of the drug, as 1999; 2000) , in studying α7-mediated currents recorded from CA1 interneurons in rat hippocampus, reported that the EC50 values for choline and nicotine were, respectively, 2270 mM and 158 mM, representing only a 14 fold difference in potencies.
Likewise there was no more than a 10 fold difference in potency between choline and nicotine in their ability to increase intracellular Ca 2++ in cultured porcine superior cervical ganglion cells (Si and Lee, 2002) . We had noted similar mismatches between binding affinity and pharmacological response earlier in studying nicotine and choline as cytoprotective agents in vitro (Jonnala et al., 2003) , so it is not likely that the differences in drug effectiveness could be attributed to differences in their brain distribution or elimination. Also, choline appears to be slightly less efficacious than nicotine though it has been characterized as a full α7nAChR agonist (Pereira et al., 2002) . Again, we had noted this potential discrepancy in our earlier cytoprotection study.
Although the effect of icv choline on heart rate was more variable than the effect on MAP, the responses appeared to be susceptible to the same antagonists as was the initial increase in MAP.
MLA pretreatment almost completely normalized the biphasic change in heart rate to choline; whereas α-bungarotoxin pretreatment appeared to inhibit only the initial tachycardic phase. The differential effect may be due to differences in drug distribution between the two antagonists, and it suggests that the two phases of the heart rate response may be mediated in different brain regions. The ability of icv-injected atropine to inhibit the heart rate changes to choline suggests This article has not been copyedited and formatted. The final version may differ from this version. , 1986) . More recently we reported that in rat models genetically manipulated to maintain an elevated blood pressure, there is a link between decreased expression of brain α7nAChRs and working memory deficits (Gattu et al., 1997; Terry et al., 2001) . In the present study the pressor response to icv-administered choline was blocked by pretreatment with the α7 subtype selective antagonists, MLA and α-bungarotoxin. The lack of effect of pretreatment with DHβE, the β2 subtype-preferring antagonist, supported the concept that the initial pressor response to choline was mediated by the α7 subtype. Of course the participation of other non-α7 containing subtypes cannot be completely ruled out at this time; but the data do fit the known specificity of choline for α7nAChRs (Papke et al., 1996; Pereira et al., 2002; Jonnala et al., 2003) . Additional support may be derived from the finding that an analog of choline, CDPcholine, also increased blood pressure and decreased heart rate after icv microinjection in rats (Savci et al., 2002) . The pressor effect was significantly reduced following pretreatment with the non-selective nicotinic antagonist, mecamylamine.
This article has not been copyedited and formatted. The final version may differ from this version. Having characterized the specificity of the receptors mediating the pressor response to choline, it was then possible to determine whether icv administration of Aβ1-42 would inhibit the subsequent pressor response to icv-injected choline. Cerebroventricular infusion, or repeated icv injection of Aβ1-42 in rats has been used to assess the various pharmacological responses induced by the peptide, particularly regarding its potential amnestic actions (Maurice et al., 1996; Yamada et al., 1998; Yamaguchi et al., 2001; Nakamura et al., 2001; Olariu et al., 2002) .
Moreover, the related peptide Aβ25-35 (15 nmol/injection) has been reported to impair shortterm working memory even after a single acute injection (Stepanichev et al., 2003) . The dose used in the memory experiment was 150 fold greater than the most effective dose we used to block the pressor response to choline.
The mechanism by which Aβ1-42 interferes with the performance of certain memory-related tasks is not clear, but the peptide has this feature in common with the nicotinic receptor antagonist mecamylamine (Elrod and Buccafusco, 1991; Hiramatsu et al., 1998; Levin and Simon, 1998) . Future studies will be required to determine whether the amnestic effects induced following central microinjection of Aβ peptides are related to their ability to bind to α7nAChRs.
Nevertheless based on the data presented here, it is clear that Aβ1-42 does produce a functional blockade of α7nAChRs at low pharmacologic doses. The specificity of the Aβ1-42 inhibition of the choline pressor response was supported by the failure of Aβ40-1 peptide (which contains the critical α7nAChR binding sequence in reverse order) to block the choline response. Although Aβ1-42 significantly inhibited the pressor response to choline, the maximal degree of inhibition amounted to about a 60% decrease relative to the control response. Clearly the nicotinic antagonists were more effective, nearly eliminating the choline-induced pressor response. This nuclei, the dorsal premammilary nucleus and the arcuate nucleus (Gattu et al., 1997; Tohyama and Takatsuji, 1998) .
In summary, these data support the concept that the pressor response to icv microinjection of choline may be used as an unbiased measure of α7nAChR stimulation in vivo. They also support the ability of acute injection of Aβ1-42 to produce a rapid functional blockade of α7nAChRs at pharmacologically (and likely physiologically in the case of AD) relevant doses. The use of telemetric catheters for monitoring cardiovascular status permits free movement of the animals and could allow for the assessment of various parameters of locomotor activity and other behaviors. Finally, some consideration should be given to the possibility that amyloid Aβ -α7nAChR interactions may play a role in the dysautonomia exhibited by some individuals with AD (Giubilei et al., 1998) . 
